OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer

September 28th 2017

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

Dr. Postow on Combination Regimens for High-Risk Melanoma

September 28th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combinations of regimens for patients with high-risk melanoma.

Dr. Weber on CheckMate-238 Compared With Other Trials in Melanoma

September 28th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.

Dr. Uzzo on the Guidelines for the Management of Kidney Cancer

September 28th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

September 28th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses strategies for developing cures for patients with locally advanced urothelial carcinoma.

Dr. Alberts Discusses Updates in Liver Cancer

September 26th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Dr. McKay Discusses the CheckMate-214 Trial in RCC

September 26th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses the CheckMate-214 study in renal cell carcinoma.

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

September 26th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

Dr. Saab on Immunotherapy in MSI-H GI Malignancies

September 23rd 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

September 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer

September 22nd 2017

Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Dr. Young Discusses Thromboembolic Events in Pediatric Cancer

September 21st 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses the occurrence of thromboembolic events in pediatric cancer.

Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

September 21st 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.

Dr. West on Lurbinectedin in SCLC

September 20th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

Dr. Leitao Discusses Surgery in Gynecologic Malignancies

September 20th 2017

Mario M. Leitao, Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses surgery in gynecologic malignancies.

Dr. Zamarin on Lenvatinib Plus Pembrolizumab in Endometrial Cancer

September 20th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in endometrial cancer.

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

Dr. Besse on the Combination of Treatments for NSCLC

September 20th 2017

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non